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To evaluate the impact of clinical audit and focused interventions on reducing cardiovascular diseases 
risk by treating Low Density Lipoprotein Cholesterol (LDL-C) in patients with type 2 diabetes attending a 
primary care clinic in Kuwait.  
Methods:  
Using LDL as a surrogate for cardiovascular risk, the audit team performed a clinical audit with focus on 
the care process indicator of statin prescription. The basic audit reviewed 100 patients’ medical records 
retrospectively to assess patients’ lipid profiles and statin prescription. A lipid management protocol and 
algorithm based on national clinical practice guidelines distributed to all healthcare professionals and 
was implemented for 3 months followed by re-audit of another 100 records. Descriptive and 
comparative statistics (pre and post) were performed using SPSS, version 22.  
Results:  
Statin prescription increased significantly from (26%) in the basic audit to (85%) in the post-intervention 
audit (p<0.001). The mean LDL-C value decreased significantly from 3.37±0.67mmol/L to 
2.71±0.79mmol/L, p<0.001. Mean total cholesterol was significantly reduced from 5.15±0.73mmol/L to 
4.68±0.88mmol/L, p<0.001. Ten years CHD risk decreased from 18.46±11.1% to 16.8±12.23%, p=0.152.  
Conclusions:  
Implementing a clinical audit coupled with focused intervention was successful in improving 
management of LDL-C among patients with type 2 diabetes mellitus attending the primary healthcare 
sector in Kuwait.  
 
Keywords: diabetes; low density lipoprotein cholesterol; audit; clinical guidelines, Kuwait.  
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Introduction: 
The prevalence of diabetes mellitus is high in North Africa and the Middle East region (9.1%) with 




type name="Web Page">12</ref-type><contributors><authors><author>International Diabetes 
Federation </author></authors></contributors><titles><title>International Diabetes Federation Atlas 
</title></titles><dates><year>2013</year></dates><urls><related-
urls><url>www.idf.org/diabetesatlas.</url></related-urls></urls></record></Cite></EndNote>} 
According to the International Diabetes Federation, Kuwait is among the top ten countries affected by 




type name="Web Page">12</ref-type><contributors><authors><author>International Diabetes 
Federation </author></authors></contributors><titles><title>International Diabetes Federation Atlas 
</title></titles><dates><year>2013</year></dates><urls><related-
urls><url>www.idf.org/diabetesatlas.</url></related-urls></urls></record></Cite></EndNote>} Several 
factors contribute to the high prevalence of diabetes in Kuwait, including the socioeconomic changes 
that followed the post-oil era, sedentary lifestyle, special food habits, increased life expectancy and 
increased risk factors for diabetes and obesity.{ ADDIN EN.CITE 
<EndNote><Cite><Author>Abdella</Author><Year>1998</Year><RecNum>4188</RecNum><DisplayTex
t>[2]</DisplayText><record><rec-number>4188</rec-number><foreign-keys><key app="EN" db-
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id="srzsexpvnewvs8ezs9qvpdf59pa09ft50tpe">4188</key></foreign-keys><ref-type name="Journal 
Article">17</ref-type><contributors><authors><author>Abdella, N.</author><author>Al Arouj, 
M.</author><author>Al Nakhi, A.</author><author>Al Assoussi, A.</author><author>Moussa, 
M.</author></authors></contributors><auth-address>Department of Medicine, Faculty of Medicine, 
Kuwait University, Safat.</auth-address><titles><title>Non-insulin-dependent diabetes in Kuwait: 
prevalence rates and associated risk factors</title><secondary-title>Diabetes Res Clin Pract</secondary-
title></titles><periodical><full-title>Diabetes Res Clin Pract</full-title></periodical><pages>187-
96</pages><volume>42</volume><number>3</number><keywords><keyword>Adult</keyword><key
word>Age Factors</keyword><keyword>Analysis of Variance</keyword><keyword>Blood 
Glucose/analysis</keyword><keyword>Body Mass 












Dyslipidemia and vascular changes that accompany diabetes accelerate the atherosclerosis 
process which is a major contributor to cardiovascular morbidity and mortality.{ ADDIN EN.CITE 





type name="Journal Article">17</ref-type><contributors><authors><author>Jenkins, A. 
J.</author><author>Best, J. D.</author><author>Klein, R. L.</author><author>Lyons, T. 
J.</author></authors></contributors><auth-address>University of Melbourne, Department of 
Medicine, St Vincent&apos;s Hospital, Fitzroy, Australia. jenkinsa@medstv.unimelb.edu.au</auth-
address><titles><title>&apos;Lipoproteins, glycoxidation and diabetic 
angiopathy&apos;</title><secondary-title>Diabetes Metab Res Rev</secondary-
title></titles><periodical><full-title>Diabetes Metab Res Rev</full-title></periodical><pages>349-
68</pages><volume>20</volume><number>5</number><keywords><keyword>Diabetes Mellitus, Type 
1/*metabolism</keyword><keyword>Diabetes Mellitus, Type 
2/*metabolism</keyword><keyword>Diabetic 






resource-num>10.1002/dmrr.491</electronic-resource-num></record></Cite></EndNote>} In a sample 
of patients with diabetes in Kuwait, total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) 
levels were found to be above the accepted level as dictated by Kuwait Diabetes Guidelines, in 67% and 
86% of the patients respectively.{ ADDIN EN.CITE <EndNote><Cite><Author>Al-
Adsani</Author><Year>2004</Year><RecNum>6</RecNum><DisplayText>[4]</DisplayText><record><r




type name="Journal Article">17</ref-type><contributors><authors><author>Al-Adsani, 
A.</author><author>Memon, A.</author><author>Suresh, 
A.</author></authors></contributors><auth-address>Department of Medicine, Al-Sabah Hospital, 
Ministry of Health, Kuwait. amsaladsani@yahoo.com</auth-address><titles><title>Pattern and 




word>Body Mass Index</keyword><keyword>Cholesterol/blood</keyword><keyword>Coronary 
Disease/epidemiology/prevention &amp; control</keyword><keyword>Diabetes Mellitus, Type 








urls></urls></record></Cite></EndNote>} Another study describing the cardiovascular disease (CVD) 
risk factors in Kuwait reported that the prevalence of dyslipidemia was 70.3% among Kuwaiti nationals 
in the age group between  20-65 years.{ ADDIN EN.CITE 
<EndNote><Cite><Author>Alarouj</Author><Year>2013</Year><RecNum>7</RecNum><DisplayText>[5




type name="Journal Article">17</ref-type><contributors><authors><author>Alarouj, 
M.</author><author>Bennakhi, A.</author><author>Alnesef, Y.</author><author>Sharifi, 
M.</author><author>Elkum, N.</author></authors></contributors><auth-address>Dasman Diabetes 
Institute, Department of Clinical Services, Kuwait City, Kuwait Kuwait Ministry of Health, Kuwait City, 
Kuwait.</auth-address><titles><title>Diabetes and associated cardiovascular risk factors in the State of 
Kuwait: the first national survey</title><secondary-title>Int J Clin Pract</secondary-
title></titles><periodical><full-title>Int J Clin Pract</full-title></periodical><pages>89-
96</pages><volume>67</volume><number>1</number><keywords><keyword>Adult</keyword><key
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There is a validated and strong association between abnormal lipid values particularly LDL-C and 
CVD risk.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} LDL-C is the principal carrier of cholesterol and is 
directly associated with atherosclerosis and cardiovascular disease risk.{ ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }} Reduction of LDL-C has been associated with decreasing CVD events.{ ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }} A meta-analysis by Kearney et al. demonstrated that for each one mmol/L 
reduction of LDL-C, there was 21% proportional reduction in major cardiovascular outcomes.{ ADDIN 




type name="Journal Article">17</ref-type><contributors><authors><author>Cholesterol Treatment 
Trialists, Collaborators</author><author>Kearney, P. M.</author><author>Blackwell, 
L.</author><author>Collins, R.</author><author>Keech, A.</author><author>Simes, 
J.</author><author>Peto, R.</author><author>Armitage, J.</author><author>Baigent, 
C.</author></authors></contributors><titles><title>Efficacy of cholesterol-lowering therapy in 18,686 




Diseases/etiology/mortality/prevention &amp; control</keyword><keyword>Cholesterol, 
LDL/blood</keyword><keyword>Diabetes Mellitus, Type 1/blood/complications/*drug 
therapy</keyword><keyword>Diabetes Mellitus, Type 2/blood/complications/*drug 
therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hydroxyme
thylglutaryl-CoA Reductase Inhibitors/*therapeutic 
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use</keyword><keyword>Male</keyword><keyword>Middle Aged</keyword><keyword>Multicenter 
Studies as Topic</keyword><keyword>Randomized Controlled Trials as 
Topic</keyword><keyword>Triglycerides/blood</keyword></keywords><dates><year>2008</year><pu




num></record></Cite></EndNote>} Statins have been shown to be effective in lowering LDL-C, and in 
reducing major coronary events in patients with diabetes in many clinical trials.{ ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }} However, some studies have highlighted the issue of under-treatment of dyslipidemia 




type name="Journal Article">17</ref-type><contributors><authors><author>Ascunce, R. 
R.</author><author>Berger, J. S.</author><author>Weintraub, H. S.</author><author>Schwartzbard, 
A.</author></authors></contributors><auth-address>Department of Medicine, Division of Cardiology, 
NYU Langone Medical Center, New York, USA, Rebecca.Ascunce@nyumc.org.</auth-
address><titles><title>The Role of Statin Therapy for Primary Prevention: What is the 
Evidence?</title><secondary-title>Curr Atheroscler Rep</secondary-title></titles><periodical><full-
title>Curr Atheroscler Rep</full-title></periodical><dates><year>2012</year><pub-dates><date>Jan 
29</date></pub-dates></dates><isbn>1534-6242 (Electronic)&#xD;1523-3804 
(Linking)</isbn><accession-num>22286194</accession-num><urls><related-




A number of studies have evaluated this relationship in patients admitted to hospitals in Kuwait. 
Saad et al. reported that the diagnosis of diabetes and elevated TC were evident in 41% and 56% of 
patients with acute myocardial infarction (MI) admitted to hospital in Kuwait.{ ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }} Patients with diabetes who were admitted to hospital after acute MI had double the 




type name="Journal Article">17</ref-type><contributors><authors><author>Thalib, 
L.</author><author>Zubaid, M.</author><author>Suresh, C. G.</author><author>Rashed, 
W.</author><author>Shukkur, M.</author></authors></contributors><auth-address>Department of 
Community Medicine and Behavioural Sciences, Faculty of Medicine, Kuwait University, PO Box 24923, 
Safat, Kuwait. lthalib@hsc.kuniv.edu.kw</auth-address><titles><title>Diabetes mellitus as a contributor 




Disease</keyword><keyword>Adult</keyword><keyword>Aged</keyword><keyword>Aged, 80 and 
over</keyword><keyword>Case-Control Studies</keyword><keyword>Coronary Care Units/*statistics 
&amp; numerical data</keyword><keyword>*Diabetes 
Complications</keyword><keyword>Female</keyword><keyword>*Hospital 
Mortality</keyword><keyword>Hospitals, University/statistics &amp; numerical 










has also been reported that 44.4% of patients admitted to hospital with MI in Kuwait were found to 




type name="Journal Article">17</ref-type><contributors><authors><author>al-Adsani, 
A.</author><author>Memon, A.</author><author>Peneva, A.</author><author>Baidas, 
G.</author></authors></contributors><auth-address>Department of Medicine, Al-Sabah Hospital, 
Kuwait. amsaladsani@myworldmail.com</auth-address><titles><title>Clinical epidemiology of acute 
myocardial infarction in Kuwait</title><secondary-title>Acta Cardiol</secondary-
title></titles><periodical><full-title>Acta Cardiol</full-title></periodical><pages>17-
23</pages><volume>55</volume><number>1</number><keywords><keyword>Adult</keyword><key















There is very little data on the quality of diabetes management and quality improvement of diabetes 




type name="Journal Article">17</ref-type><contributors><authors><author>Alhyas, 
L.</author><author>McKay, A.</author><author>Majeed, 
A.</author></authors></contributors><auth-address>Department of Primary Care &amp; Public Health, 
Imperial College London, London, United Kingdom. l.alhyas08@imperial.ac.uk</auth-
address><titles><title>Prevalence of type 2 diabetes in the States of the co-operation council for the 




</keyword><keyword>Diabetes Mellitus, Type 









are also limited reports in the literature evaluating lipid management practices in patients with diabetes 




type name="Journal Article">17</ref-type><contributors><authors><author>Al-Adsani, 
A.</author><author>Memon, A.</author><author>Suresh, 
A.</author></authors></contributors><auth-address>Department of Medicine, Al-Sabah Hospital, 
Ministry of Health, Kuwait. amsaladsani@yahoo.com</auth-address><titles><title>Pattern and 




word>Body Mass Index</keyword><keyword>Cholesterol/blood</keyword><keyword>Coronary 
Disease/epidemiology/prevention &amp; control</keyword><keyword>Diabetes Mellitus, Type 
2/*blood</keyword><keyword>Diabetic Angiopathies/epidemiology/prevention &amp; 
control</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hyperlipide








urls></urls></record></Cite></EndNote>} where most patients with diabetes are followed in the 
primary healthcare (PHC) sector. Kuwait Diabetes Guidelines recommend using statin therapy to lower 




type name="Web Page">12</ref-type><contributors><authors><author>Ministry of 




l%20Guideline%202014.pdf</url></related-urls></urls></record></Cite></EndNote>} The intermediate 
outcomes, LDL-C and glycosylated hemoglobin (HbA1c), are frequently used to measure the quality of 




type name="Journal Article">17</ref-type><contributors><authors><author>Adiseshiah, 
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M.</author></authors></contributors><auth-address>University College London NHS Foundation Trust 
Hospitals, Middlesex Hospital, London W1N 8AA, UK. maria.adiseshiah@uclh.org</auth-
address><titles><title>Effective care of patients with type 2 diabetes and dyslipidemia: a nurse&apos;s 
perspective</title><secondary-title>Diabetes Res Clin Pract</secondary-title></titles><periodical><full-
title>Diabetes Res Clin Pract</full-title></periodical><pages>S23-7</pages><volume>68 Suppl 
2</volume><keywords><keyword>Diabetes Mellitus, Type 
2/*complications/epidemiology/nursing</keyword><keyword>Humans</keyword><keyword>Hyperlipi







Therefore, improving the care process indicators (proper management of dyslipidemia by using the 
evidence-based therapy such as statins), and intermediate outcomes (LDL-C) can improve the clinical 
outcomes of patients with diabetes treated at PHC in Kuwait. 
This study explored the impact of implementing a protocol based intervention on reducing the 
CVD risk in patients with type 2 diabetes by improving management of LDL-C. As a secondary outcome, 
the audit measured the percentage of patients with type 2 diabetes who were on statin therapy, and the 
percentage of patients using statins who achieved the target goal of LDL-C (2.6 mmol/L).  
 
 





The governmental PHC sector of Kuwait consists of a number of polyclinics distributed over the different 
areas of the State of Kuwait to serve the healthcare needs of the population. This audit was conducted 
at Al-Naeem Diabetes Clinic, part of the primary healthcare polyclinic, Jahra health area, State of Kuwait.  
Study Design 
This study was a cross-sectional retrospective clinical audit focusing on LDL-C management in patients 
with type 2 diabetes.. The guidelines used in this study were Kuwait Clinical Practice Guidelines-
Diabetes Mellitus, the Scottish Intercollegiate Guideline Network on management of diabetes 
(SIGN) and National Institute for Health and Care Excellence (NICE) clinical guideline 181. { 
ADDIN EN.CITE { ADDIN EN.CITE.DATA }} Primary prevention of CVD requires that people with 
diabetes apply healthy lifestyle changes and are offered to use statins at age 40. Kuwait 
guidelines recommends using <2.6mmol/L as target value for LDL-C and 1.8mmol/L if there is 
evident CVD.19  Statins such as simvastatin 40 mg, atorvastatin 10 mg and 20 mg were available 
and could be prescribed for the primary prevention of CVD at the time of this study. To complete 
the audit cycle, a basic audit was initially conducted; then a three-month intervention phase was 
implemented followed by a post-intervention audit. Data were retrospectively collected from the paper 
medical records from a computer generated random sample of record numbers for 100 patients with 
type 2 diabetes in both the basic and follow-up audits.  
In the basic audit, the care process that we assessed was the management of LDL-C, using ≥ 
2.6mmol/l as a cutoff level as a recommended target in Kuwait Diabetes Clinical Practice Guidelines.19 
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The intermediate outcome included the average LDL-C values, number of eligible patients on statin 
therapy and statin dose intensification. The basic audit identified deficiencies in the practices of 
management of high LDL-C when results were compared to guidelines standards. { ADDIN EN.CITE { 
ADDIN EN.CITE.DATA }}  
Following the basic audit, an intervention phase was implemented which included applying a 
locally agreed protocol for lipid management based on lipid management recommendations in Kuwait 
Diabetes Clinical Practice Guidelines, NICE and SIGN recommendations on LDL-C management.{ ADDIN 
EN.CITE { ADDIN EN.CITE.DATA }} All healthcare professionals working at Al Naeem Polyclinic received a 
copy of the protocol and an algorithm. Nurses and laboratory technicians were advised to highlight all 
laboratory results of LDL-C of 2.6 mmol/L or higher and forward it immediately to the corresponding 
treating physician. Following a presentation about audit, the healthcare team adopted the concept of 
audit as a practical way of improving the care process and the clinic reputation. Patients older than 40 
years were informed by their 10 years CHD risk and were offered the choice to start statin therapy 
(simvastatin or atorvastatin) for the purpose of primary prevention. Subjects younger than 40 years with 
more than one risk factor were offered statin for primary prevention. For patients younger than 40 years 
with no risk factors but with LDL-C ≥ 2.6mmol/L, statin therapy was considered by a joint decision taken 
with the patient. Lifestyle modifications, including weight management, increasing physical activity and 
smoking cessation were discussed with every patient with diabetes attending the clinic. Patients were 
also offered printed educational materials focussing on healthy food choices and encouraging physical 
activity. Following the 3-month intervention, a re-audit was conducted to assess the changes in the 
process of care (prescription of statins to eligible persons), and in the intermediate outcome (changes in 
LDL-C and TC values). 
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Sample selection  
In each audit cycle, the audit team choose to randomly sample one hundred medical records of patients. 
Records were randomly selected from a computer generated list. Inclusion criteria were age between 
40-80 years old, a diagnosis of type 2 diabetes for more than one year, LDL level >2.6mmol/L, and 
evidence of at least two visits to the clinic within one year of data collection. Patients who were using 
fibrates or any other lipid lowering agents were excluded from this study. 
Data collection 
A data collection sheet was used to record patients’ clinical information. The variables assessed in each 
audit cycle included patient's demographics, biochemical laboratory results, diabetes duration, systolic 
and diastolic blood pressure, body mass index (BMI), smoking history, lipid modifying medications,  
Statistical Analysis  
The Statistical Package for Social Sciences (IBM SPSS Statistics version 22) was used for data analysis. 
The independent samples t-test was used for normally distributed data. The non-parametric test (Mann 
Whitney) was used to compare data of the basic audit and the re-audit when data were not normally 
distributed. Continuous variables were reported as the mean±SD and categorical variables were 
reported as percentages. 
 Ethical Approval 
Ethical approval was received from Dasman Diabetes Institute (Institutional Review Board [IRB] number: 
RA 2013-21). The selected medical records were anonymised and identified by numbers only to ensure 
the confidentiality of study subjects. 
Results: 
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Patient characteristics in basic and post-intervention audits 
Table 1 shows the characteristics of the pre-audit and post-audit cohorts. A total of 200 medical records 
were examined. The mean age of patient's ± SD was 52.4 ± 9 years in the basic audit and 52.5 ± 9.2 years 
in the re-audit. A total of 200 patients over the age 40 years (100 in the basic audit and 100 in the re-
audit) were included, of whom 78 were females (41 in the basic audit and 37 in the re-audit). There 
were no significant statistical differences between the age, gender or nationality of patients, nor in 
diabetes duration, BMI and smoking between the pre- and post-intervention audits.  
Statin therapy and dose titration  
Out of 100 records examined in the baseline audit, only 26% of patients were on statin therapy. Most of 
those (20 cases) were on a low dose statin (simvastatin 20 mg). There was a significant increase in the 
number of patients receiving statin therapy in the post-intervention audit (85%) compared to 26% in 
baseline audit (p<0.001). Dose intensification was also higher in the post-intervention audit than the 
baseline audit and the difference was significant (p<0.005). Table 2 outlines the use of statin therapy; 
type of statin; dose; and titration of therapy. 
Clinical and laboratory findings 
Table 3 outlines the clinical and laboratory data of participants in basic and post-intervention audits. 
There was an improvement in the lipid profile in the post intervention audit. TC levels were significantly 
reduced from 5.15±0.73 mmol/l to 4.68±0.88 mmol/L and LDL-C from 3.37±0.67 to 2.71±0.79 mmol/L in 
the post-intervention audit (p<0.001). Triglycerides levels (TG) were lower, and high density lipoprotein 
(HDL) levels were numerically higher in the post-intervention audit; however, these changes did not 
reach statistical significance. CV risk calculation showed a statistically non-significant reduction in the 
post intervention phase (from 18.46±11.1% to 16.8±12.23%). There were no significant statistical 
differences between the levels of liver enzymes (ALT/AST), fasting blood glucose, serum creatinine and 
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number of insulin units between the pre- and post-intervention audits. Serum creatinine, fasting blood 
glucose and insulin units were slightly higher in the post intervention audit but the changes did not 
reach statistical significance.  
 
Discussion:  
This study aimed at improving the quality of care with regards to management of dyslipidemia in 
patients with diabetes followed at one primary care diabetes clinic in Kuwait. Clinical audits and 
feedback serve as quality improvement strategy that can minimize the gap between evidence-based 
recommendations and real-life actual practice. The audit cycle reported in this study focused on the care 
process indicator (prescription of statins to eligible persons with diabetes), and the intermediate 
outcomes of diabetes care (reduction of LDL-C levels and appropriate dose titration of statins) using a 
protocol-driven intervention.  
The study identified deficiencies in lipid management in these patients (high level of average 
LDL-C and under-use of statin therapy). This was subsequently targeted by focused interventions which 
resulted in improved quality of care as evident in the results of the re-audit cycle. The interventions 
resulted in a significant, rapid, and marked improvement in key diabetes standards, including significant 
reduction of TC and LDL-C values, significant increase of statin prescriptions; and dose titration to match 
tolerance of eligible patients with type 2 diabetes.  
The baseline audit cycle showed that many patients with type2 diabetes in the primary care 
sector have lipid values above treatment thresholds and management of dyslipidemia was suboptimal, 
leaving people at high cardiovascular risk. Diabetic dyslipidemia is under-treated in many countries.{ 
ADDIN EN.CITE <EndNote><Cite><Author>Kolding 
Kristensen</Author><Year>2006</Year><RecNum>50</RecNum><DisplayText>[23]</DisplayText><reco




type name="Journal Article">17</ref-type><contributors><authors><author>Kolding Kristensen, 
J.</author><author>Lauritzen, T.</author></authors></contributors><auth-address>Department of 
General Practice, University of Aarhus, Aarhus, Denmark. jkk@alm.au.dk</auth-
address><titles><title>Inadequate treatment of dyslipidemia in people with type 2 diabetes: quality 
assessment of diabetes care in a Danish County</title><secondary-title>Scand J Prim Health 




d>Diabetes Mellitus, Type 2/blood/complications/*drug 
therapy</keyword><keyword>Dyslipidemias/blood/complications/*drug 
therapy</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hypolipide
mic Agents/*therapeutic use</keyword><keyword>Male</keyword><keyword>Middle 







The findings of this study shows that 74% patients with type 2 diabetes who are eligible to statin therapy 
did not receive a statin. In a study conducted by Braga et al. in Canada, 43% of patients with type 2 
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diabetes with high LDL-C (>2.6mmol/L) did not receive statin therapy.{ ADDIN EN.CITE { ADDIN 
EN.CITE.DATA }} Possible explanation for the under prescription of statins in this patient population is 
that patients with diabetes are on multiple medications and therefore, willingness to be prescribed 
another therapy is low .{ ADDIN EN.CITE 
<EndNote><Cite><Author>Parris</Author><Year>2005</Year><RecNum>205</RecNum><DisplayText>[25]</DisplayText><record><rec-number>205</rec-
number><foreign-keys><key app="EN" db-id="d0tf9p5wleartpe02fmpdzadrzt5pdxsadza">205</key></foreign-keys><ref-type name="Journal Article">17</ref-
type><contributors><authors><author>Parris, E. S.</author><author>Lawrence, D. B.</author><author>Mohn, L. A.</author><author>Long, L. 
B.</author></authors></contributors><auth-address>Pfizer, Clinical Education Consultants, 400 Perimeter Center Terrace, Suite 1000, Atlanta, GA 30346, 
USA.</auth-address><titles><title>Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia</title><secondary-
title>Diabetes Care</secondary-title><alt-title>Diabetes care</alt-title></titles><periodical><full-title>Diabetes Care</full-title><abbr-1>Diabetes care</abbr-
1></periodical><alt-periodical><full-title>Diabetes Care</full-title><abbr-1>Diabetes care</abbr-1></alt-periodical><pages>595-
9</pages><volume>28</volume><number>3</number><edition>2005/03/01</edition><keywords><keyword>Anticholesteremic Agents/ therapeutic 
use</keyword><keyword>Cholesterol, LDL/ blood/drug effects</keyword><keyword>Databases, Factual</keyword><keyword>Diabetes Complications/ 
blood</keyword><keyword>Female</keyword><keyword>Health Maintenance 
Organizations</keyword><keyword>Humans</keyword><keyword>Hyperlipidemias/blood/ drug 




Results of the baseline audit motivated the healthcare team to adopt a local protocol of lipid 
management and implement prescription of statins as a primary prevention strategy to patients with 
type 2 diabetes over the age of 40 years. There was also reduction in the TG and elevation of the HDL-C 
values, but these changes were not statistically significant. These findings were the direct effect of 
prescribing statin therapy to eligible people with type 2 diabetes (age > 40 years, LDL-C ≥ 2.6mmol/L and 
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with CHD risk ≥ 20 as measured by the UKPDS risk engine). Reduction of TC and LDL-C levels is a major 
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improvement in LDL values shortly after implementing an agreed upon lipid management protocol.{ 
ADDIN EN.CITE { ADDIN EN.CITE.DATA }} Results of a clinical audit on diabetes care in patients with type 
2 diabetes in the United Arab Emirates showed improvement in LDL-C but that did not reach a 
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TRANSLATE trial used a multicomponent intervention to improve diabetes care in community primary 
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care practices which resulted in significant increase in the percentage of patients with type 2 diabetes 
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The intervention implemented in the study also resulted in a significant improvement in lipid 
management strategy by increasing the number of patients receiving statins from 26 % in the basic audit 
to 85% in the post-intervention audit. Another positive effect was noticed with regards to the dose 
intensification to the effective therapeutic dose (simvastatin 40 mg and atorvastatin 20 mg). Dose 
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be attributed to the effect of the intervention and feedback of the audit cycle that focused on LDL-C as 
the primary lipid target in primary prevention of CVD in patients with diabetes. The lower rate of statin 
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prescription, the low doses used, and the high baseline LDL-C in the baseline audit could have 
contributed to the significant improvement noticed in the re-audit.  
It is hoped that the reduction of TC and LDL-C values would lead to a reduction in longer-term 
micro- and macro-vascular complications of diabetes. In this study, it is evident that obesity represents a 
risk factor among patients with diabetes. The high average BMI (30.5 Kg/m2) reported is consistent with 
findings of other studies conducted in Kuwait.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} Initiating statin 
therapy in eligible patients did not seem to result in significant statistical differences in the laboratory 
values of fasting blood glucose, liver enzymes (ALT/AST), serum creatinine and number of insulin units 
between the pre- and post-intervention audits. This could be attributed to the fact that the patients 
received statin therapy only for a short time duration (three months or less). 
A key issue in any quality improvement project is maintaining enthusiasm of the primary care 
team in the setting of a busy clinic to continue to adhere to the protocol. A plan to re-audit this practice 
in the near future to determine if the improvement achieved has been maintained and to further 
investigate management of other cardiovascular risk factors, blood pressure, blood glucose control, and 
smoking in addition to lipid management. Also the spectrum will include the impact of patient 
education, lifestyle changes, improving patient concordance with prescribed therapy as an example of 
patient centered intervention tools to normalize lipid values and reduce CVD risk. Future consideration 
of incentivizing good practice may be required as demonstrated by the implementation of Quality 
Outcomes Framework (QOF) in the UK where deaths from any cause and those related to specific 
conditions included in QOF – such as diabetes, hypertension and heart failure – declined over the period 
three to eight years after QOF was introduced.{ ADDIN EN.CITE { ADDIN EN.CITE.DATA }} 
Study limitations and difficulties   
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This study had a number of limitations. The first hundred patients were not followed up in the re-audit. 
This was due to the unpredictable nature of clinic attendances of this population which largely consisted 
of migrant workers. However, both cohorts were comparable and further provides some assurance of 
this audit model for audits in this setting. Electronic medical records were still in the early stage of 
implementation at the clinic at the time of the study. Electronic records would make it easier to study a 
larger sample more easily. Being conducted over a short period of time, and on a relatively limited 
number of patients, it was difficult to assess the effect of statins on glucose homeostasis or to evaluate 
the possible side effects of statins on these patients. Medications that may influence lipid profile (e.g. 
thiazolidinediones [TZDs], Glucagon-like peptide-1 receptor agonists [GLP-1 RA], and the sodium/glucose 
cotransporter 2 [SGLT2] inhibitors) were not available the time when the study was conducted. 
 
Conclusions  
Dyslipidemia is directly related to cardiovascular morbidity and mortality in patients with type 2 
diabetes, yet it seems to be under-treated in many countries. A clinical audit was effective in improving 
management of LDL-C in patients with type 2 diabetes attending a primary healthcare diabetes clinic in 
Kuwait. The basic audit revealed under-treatment of dyslipidemia which was evident as high LDL-C 
levels, low rate of statins prescription in patients eligible for stain therapy, and improper doses of 
statins. The implementation of a three-month intervention including a lipid management protocol 
resulted in significant reduction in TC and LDL-C values, significant increase in the number of patients 
prescribed statin therapy and in dose intensification. Clinical audit coupled with planned interventions 
can serve as effective and practical tool to improve management of cardiovascular risk factors in 
patients with type 2 diabetes in primary care practice but changes in clinical practice need to be 
maintained. 
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A Clinical Audit to Assess Management of Low Density Lipoprotein Cholesterol at a Primary Care 
Diabetes Clinic in Kuwait 
 






























































S m o k i n g 
 
 





1 3  ( 1 3 . 0 ) 
8 5  ( 8 5 . 0 ) 
2  ( 2 . 0 ) 
 
 
1 2  ( 1 2 . 0 ) 
8 8  ( 8 8 . 0 ) 
0 ( 0 . 0 ) 
 
 
0 . . 8 4 0 
 
*P value is significant if <0.05. NK: non-Kuwaiti BMI: body mass index. Ex: former smoker. 
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Table 2: The use of statin therapy; type of statin; dose; and titration of therapy 













































































*P value is significant if <0.05. Simva: Simvastatin; Atorva: Atorvastatin.  
**P value true for all comparisons of each dose of each agent 
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133.74 ± 15.55 
 
 








83.59 ± 8.11 
 
 









9.09 ± 2.14 
 
 








5.15 ± 0.73 
 
 















3.37 ± 0.67 
 
 






1.07 ± 0.24 
 
 





24.47 ± 14.51 20.88 ± 9.76 0.172 
AST 
(U/L) 
21.50 ± 9.44 18.77 ± 5.54 0.192 
Creatinin 
(umol/L) 
62.79 ± 26.66 64.63 ± 24.91 0.262 
FBG 
(mmo/l) 
10.46 ± 4.61 11.05 ± 4.49 0.215 
Insulin 
(u/ml) 
15.18 ± 26.82 15.56 ± 24.31 0.545 
*P value is significant if <0.05. TG: Triglycerides; HbA1c: Glycosylated Hemoglobin; TC: Total Cholesterol; 
HDL: High Density Lipoprotein Cholesterol; and LDL: Low Density Lipoprotein Cholesterol; ALT.: Alanine 
Aminotransferase; AST: Aspartate Aminotransferase, FBG; Fasting Plasma Glucose 
